TY - JOUR
T1 - Structural basis of ligand recognition at the human MT1 melatonin receptor
AU - Stauch, Benjamin
AU - Johansson, Linda C.
AU - McCorvy, John D.
AU - Patel, Nilkanth
AU - Han, Gye Won
AU - Huang, Xi Ping
AU - Gati, Cornelius
AU - Batyuk, Alexander
AU - Slocum, Samuel T.
AU - Ishchenko, Andrii
AU - Brehm, Wolfgang
AU - White, Thomas A.
AU - Michaelian, Nairie
AU - Madsen, Caleb
AU - Zhu, Lan
AU - Grant, Thomas D.
AU - Grandner, Jessica M.
AU - Shiriaeva, Anna
AU - Olsen, Reid H.J.
AU - Tribo, Alexandra R.
AU - Yous, Saïd
AU - Stevens, Raymond C.
AU - Weierstall, Uwe
AU - Katritch, Vsevolod
AU - Roth, Bryan L.
AU - Liu, Wei
AU - Cherezov, Vadim
N1 - Funding Information:
Acknowledgements We thank M. Chu, C. Hanson, K. Villers, J. Velasquez, and H. Shaye for technical support, and D.R. Mende for useful discussion of sequence analysis. This research was supported by the National Institutes of Health (NIH) grants R35 GM127086 (V.C.), R21 DA042298 (W.L.), R01 GM124152 (W.L.), R01 MH112205 (B.L.R.), and U24DK116195 (B.L.R.), the NIMH Psychoactive Drug Screening Program contract (B.L.R.), F31-NS093917 (R.H.J.O.), the National Science Foundation (NSF) BioXFEL Science and Technology Center 1231306 (B.S., W.L., U.W., T.D.G., V.C.), EMBO ALTF 677-2014 (B.S.), HFSP long-term fellowship LT000046/2014-L (L.C.J.), and a postdoctoral fellowship from the Swedish Research Council (L.C.J.). C.G. thanks the SLAC National Accelerator Laboratory and the Department of Energy for financial support through the Panofsky fellowship. T.A.W. and W.B. acknowledge financial support from the Helmholtz Association via Programme-Oriented Funding. Parts of this research were carried out at the LCLS, a National User Facility operated by Stanford University on behalf of the US Department of Energy and supported by the US Department of Energy Office of Science, Office of Basic Energy Sciences under Contract No. DE-AC02-76SF00515.
Publisher Copyright:
© 2019, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2019/5/9
Y1 - 2019/5/9
N2 - Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that maintains circadian rhythms1 by synchronization to environmental cues and is involved in diverse physiological processes2 such as the regulation of blood pressure and core body temperature, oncogenesis, and immune function3. Melatonin is formed in the pineal gland in a light-regulated manner4 by enzymatic conversion from 5-hydroxytryptamine (5-HT or serotonin), and modulates sleep and wakefulness5 by activating two high-affinity G-protein-coupled receptors, type 1A (MT1) and type 1B (MT2)3,6. Shift work, travel, and ubiquitous artificial lighting can disrupt natural circadian rhythms; as a result, sleep disorders affect a substantial population in modern society and pose a considerable economic burden7. Over-the-counter melatonin is widely used to alleviate jet lag and as a safer alternative to benzodiazepines and other sleeping aids8,9, and is one of the most popular supplements in the United States10. Here, we present high-resolution room-temperature X-ray free electron laser (XFEL) structures of MT1 in complex with four agonists: the insomnia drug ramelteon11, two melatonin analogues, and the mixed melatonin–serotonin antidepressant agomelatine12,13. The structure of MT2 is described in an accompanying paper14. Although the MT1 and 5-HT receptors have similar endogenous ligands, and agomelatine acts on both receptors, the receptors differ markedly in the structure and composition of their ligand pockets; in MT1, access to the ligand pocket is tightly sealed from solvent by extracellular loop 2, leaving only a narrow channel between transmembrane helices IV and V that connects it to the lipid bilayer. The binding site is extremely compact, and ligands interact with MT1 mainly by strong aromatic stacking with Phe179 and auxiliary hydrogen bonds with Asn162 and Gln181. Our structures provide an unexpected example of atypical ligand entry for a non-lipid receptor, lay the molecular foundation of ligand recognition by melatonin receptors, and will facilitate the design of future tool compounds and therapeutic agents, while their comparison to 5-HT receptors yields insights into the evolution and polypharmacology of G-protein-coupled receptors.
AB - Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that maintains circadian rhythms1 by synchronization to environmental cues and is involved in diverse physiological processes2 such as the regulation of blood pressure and core body temperature, oncogenesis, and immune function3. Melatonin is formed in the pineal gland in a light-regulated manner4 by enzymatic conversion from 5-hydroxytryptamine (5-HT or serotonin), and modulates sleep and wakefulness5 by activating two high-affinity G-protein-coupled receptors, type 1A (MT1) and type 1B (MT2)3,6. Shift work, travel, and ubiquitous artificial lighting can disrupt natural circadian rhythms; as a result, sleep disorders affect a substantial population in modern society and pose a considerable economic burden7. Over-the-counter melatonin is widely used to alleviate jet lag and as a safer alternative to benzodiazepines and other sleeping aids8,9, and is one of the most popular supplements in the United States10. Here, we present high-resolution room-temperature X-ray free electron laser (XFEL) structures of MT1 in complex with four agonists: the insomnia drug ramelteon11, two melatonin analogues, and the mixed melatonin–serotonin antidepressant agomelatine12,13. The structure of MT2 is described in an accompanying paper14. Although the MT1 and 5-HT receptors have similar endogenous ligands, and agomelatine acts on both receptors, the receptors differ markedly in the structure and composition of their ligand pockets; in MT1, access to the ligand pocket is tightly sealed from solvent by extracellular loop 2, leaving only a narrow channel between transmembrane helices IV and V that connects it to the lipid bilayer. The binding site is extremely compact, and ligands interact with MT1 mainly by strong aromatic stacking with Phe179 and auxiliary hydrogen bonds with Asn162 and Gln181. Our structures provide an unexpected example of atypical ligand entry for a non-lipid receptor, lay the molecular foundation of ligand recognition by melatonin receptors, and will facilitate the design of future tool compounds and therapeutic agents, while their comparison to 5-HT receptors yields insights into the evolution and polypharmacology of G-protein-coupled receptors.
UR - http://www.scopus.com/inward/record.url?scp=85064887125&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064887125&partnerID=8YFLogxK
U2 - 10.1038/s41586-019-1141-3
DO - 10.1038/s41586-019-1141-3
M3 - Article
C2 - 31019306
AN - SCOPUS:85064887125
SN - 0028-0836
VL - 569
SP - 284
EP - 288
JO - Nature
JF - Nature
IS - 7755
ER -